Rocket Pharmaceuticals Stock In The News
| RCKT Stock | USD 7.59 0.29 3.68% |
Our overall analysis of Rocket Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Rocket Pharmaceuticals. The specific impact of Rocket Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Rocket Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Rocket Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Rocket Pharmaceuticals Backtesting and Rocket Pharmaceuticals Hype Analysis. For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.
Rocket |
Rocket Pharmaceuticals Today Top News and Investor Outlook
Rocket Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Rocket and other traded companies coverage with news coverage. We help investors stay connected with Rocket headlines for the 30th of March to make an informed investment decision based on correlating the impacts of news items on Rocket Stock performance. Please note that trading solely based on the Rocket Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Rocket Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Rocket earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Rocket Pharmaceuticals that are available to investors today. That information is available publicly through Rocket media outlets and privately through word of mouth or via Rocket internal channels. However, regardless of the origin, that massive amount of Rocket data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Rocket Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Rocket Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Rocket Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Rocket Pharmaceuticals alpha.
Rocket Largest EPS Surprises
Earnings surprises can significantly impact Rocket Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-08-08 | 2018-06-30 | -0.36 | -0.4 | -0.04 | 11 | ||
2020-08-05 | 2020-06-30 | -0.51 | -0.45 | 0.06 | 11 | ||
2020-11-04 | 2020-09-30 | -0.46 | -0.53 | -0.07 | 15 | ||
2022-11-03 | 2022-09-30 | -0.79 | -0.87 | -0.08 | 10 | ||
2018-05-11 | 2018-03-31 | -0.33 | -0.42 | -0.09 | 27 | ||
2025-02-24 | 2024-12-31 | -0.7179 | -0.62 | 0.0979 | 13 |
Rocket Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Rocket Pharmaceuticals Stock. Current markets are strongly bearish. About 72% of major world exchanges and indexes are down. See today's market update for more information.
19th of March 2025
Rocket Pharmaceuticals, Inc. Holdings Boosted by Privium Fund Management B.V. at thelincolnianonline.com
13th of March 2025
Acquisition by Shah Gaurav of 81655 shares of Rocket Pharmaceuticals subject to Rule 16b-3 at MacroaxisInsider
10th of March 2025
Dana Investment Advisors Inc. Has 221,000 Holdings in Rocket Pharmaceuticals, Inc. at thelincolnianonline.com
5th of March 2025
Equities Analysts Offer Predictions for RCKT FY2029 Earnings at thelincolnianonline.com
4th of March 2025
Rocket Pharmaceuticals Announces Earnings Results at thelincolnianonline.com
28th of February 2025
Rocket Pharmaceuticals Rings the Nasdaq Stock Market Opening Bell - Nasdaq at news.google.com
26th of February 2025
Selling Rocket Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have ... at simplywall.st
25th of February 2025
Disposition of 6532 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 10.58 subject... at Jonathan Schwartz
21st of February 2025
Disposition of 16303 shares by Shah Gaurav of Rocket Pharmaceuticals at 10.58 subject to R... at Shah Gaurav
14th of February 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
13th of February 2025
Acquisition by Militello John of 20080 shares of Rocket Pharmaceuticals subject to Rule 16... at Militello John
12th of February 2025
KBRA Assigns Preliminary Ratings to RCKT Mortgage Trust 2025-CES2 at businesswire.com
11th of February 2025
Acquisition by Militello John of 29920 shares of Rocket Pharmaceuticals at 9.88 subject to... at Militello John
7th of February 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
6th of February 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
3rd of February 2025
Acquisition by Pratumsuwan Piratip of 22443 shares of Rocket Pharmaceuticals at 10.56 subj... at Pratumsuwan Piratip
30th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
29th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at MacroaxisInsider
28th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
27th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
24th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
23rd of January 2025
Disposition of 896 shares by Militello John of Rocket Pharmaceuticals at 10.38 subject to ... at Militello John
22nd of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
21st of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
17th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
16th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
14th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at businesswire.com
13th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
10th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
8th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
7th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
6th of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
3rd of January 2025
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
31st of December 2024
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subjec... at Jonathan Schwartz
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rocket Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rocket Pharmaceuticals' short interest history, or implied volatility extrapolated from Rocket Pharmaceuticals options trading.
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.